70
Participants
Start Date
January 24, 2024
Primary Completion Date
April 1, 2028
Study Completion Date
June 1, 2028
Adalimumab
Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
RECRUITING
NorthShore University HealthSystem, Glenview
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Endeavor Health
OTHER